Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
  • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/4965—Non-condensed pyrazines
  • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
  • Y02P20/00—Technologies relating to chemical industry
  • Y02P20/50—Improvements relating to the production of bulk chemicals
  • Y02P20/582—Recycling of unreacted starting or intermediate materials

Definitions

• This invention relates to substituted benzothiazoles and thiazolopyridines that are useful as antibacterial agents.
• Type Il topoisomerases catalyse the interconversion of DNA topoisomers by transporting one DNA segment through another.
• Bacteria encode two type Il topoisomerase enzymes, DNA gyrase and DNA topoisomerase IV.
• Gyrase controls DNA supercoiling and relieves topological stress. Topoisomerase IV decatenates daughter chromosomes following replication and can also relax supercoiled DNA.
• Bacterial type Il topoisomerases form a heterotetrameric complex composed of two subunits. Gyrase forms an A 2 B 2 complex comprised of GyrA and GyrB whereas topoisomerase forms a C 2 E 2 complex comprised of ParC and ParE.
• eukaryotic type Il topoisomerases are homodimers.
• an antibiotic based on the inhibition of bacterial type Il topoisomerases would be selective for the bacterial enzymes and be relatively inactive against the eukaryotic type Il isomerases.
• the type Il topoisomerases are highly conserved enzymes allowing the design of broad-spectrum inhibitors.
• the GyrB and ParE subunits are functionally similar, having an ATPase domain in the N-terminal domain and a C-terminal domain that interacts with the other subunit (GyrA and ParC respectively) and the DNA.
• the conservation between the gyrase and topoisomerase IV active sites suggests that inhibitors of the sites might simultaneously target both type Il topoisomerases. Such dual-targeting inhibitors are attractive because they have the potential to reduce the development of target-based resistance.
• Type Il topoisomerases are the target of a number of antibacterial agents. The most prominent of these agents are the quinolones.
• the original quinolone antibiotics included nalidixic acid, cinoxacin and oxolinic acid.
• the addition of fluorine yielded a new class of drugs, the fluoroquinolones, which have a broader antimicrobial spectrum and improved pharmacokinetic properties.
• the fluoroquinolones include norfloxacin, ciprofloxacin, and fourth generation quinolones gatifloxacin and moxifloxacin.
• the coumarins and the cyclothialidines are further classes of antibiotics that inhibit type Il topoisomerases, however they are not widely used because of poor permeability in bacteria, eukaryotic toxicity, and low water solubility.
• antibiotics include novobiocin and coumermycin A1 , cyclothialidine, cinodine, and clerocidin.
• WO 02/060879, WO 03/105846 and WO 2005/012292 relate to benzimidazole, and pyridoimidazole compounds which inhibit bacterial gyrase activity.
• alternative compounds that inhibit bacterial topoisomerases are required.
• This invention is based on the finding that a class of substituted benzothiazoles and thiazolopyridines has antibacterial activity, as evidenced by inhibition of bacterial growth by members of that class.
• the compounds exhibit activity against strains of Gram-positive, Gram-negative and atypical bacteria, such as staphylococci, enterococci, streptococci, haemophili, moraxellas, chlamydophilas, legionellas and mycoplasmas for example Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Enterococcus faecium, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Moraxella catarrhalis, Chlamydophila pneumonia, Legionella pneumophila and Mycoplasma pneumoniae.
• the compounds with which the invention is concerned are therefore useful for the treatment of bacterial infection or contamination, for example
• the invention therefore encompasses the antibacterial use of the class of substituted benzothiazole and thiazolopyridine compounds defined herein, and to novel members of that class of compounds.
• m is 0 or 1 ;
• Q is hydrogen or cyclopropyl
• AIk is an optionally substituted, divalent C 1 -C 6 alkylene, alkenylene or alkynylene radical which may contain an ether (-O-), thioether (-S-) or amino (-NR)- link, wherein R is hydrogen, -CN or C 1 -C 3 alkyl;
• Z is N or CH, or CF
• R 2 is a group Q 1 -[Alk 1 ] q -Q 2 -, wherein q is 0 or 1;
• AIk 1 is an optionally substituted, divalent, straight chain or branched C 1 -C 6 alkylene, or C 2 -C 6 alkenylene or C 2 -C 6 alkynylene radical which may contain or terminate in an ether (-O-), thioether (-S-) or amino (-NR)- link;
• Q 2 is an optionally substituted divalent monocyclic carbocyclic or heterocyclic radical having 5 or 6 ring atoms or an optionally substituted divalent bicyclic carbocyclic or heterocyclic radical having 9 or 10 ring atoms;
• Q 1 is hydrogen, an optional substituent, or an optionally substituted carbocyclic or heterocyclic radical having 3-7 ring atoms;
• R 3 is a group Q 4 -[Alk 2 ] p -[Q 3 ] q - other than hydrogen wherein p and q are independently 0 or 1 ;
• AIk 2 is optionally substituted divalent Ci-C 6 alkylene or C 2 -C 6 alkenylene or C 2 -C 6 alkynylene radical;
• Q 3 is an optionally substituted divalent monocyclic carbocyclic or heterocyclic radical having 5 or 6 ring atoms or an optionally substituted divalent bicyclic carbocyclic or heterocyclic radical having 9 or 10 ring atoms;
• Q 4 is hydrogen, an optional substituent, or optionally substituted carbocyclic or heterocyclic having 3-7 ring atoms.
• the invention includes:
• (C a -C b )alkyl wherein a and b are integers refers to a straight or branched chain alkyl radical having from a to b carbon atoms.
• a 1 and b is 6, for example, the term includes methyl, ethyl, n-propyl, isopropyl, n- butyl, isobutyl, sec-butyl, t-butyl, n-pentyl and n-hexyl.
• divalent (C a -C b )alkylene radical wherein a and b are integers refers to a saturated hydrocarbon chain having from a to b carbon atoms and two unsatisfied valences.
• the term includes, for example, methylene, ethylene, n-propylene and n-butylene.
• (C a -C b )alkenyl wherein a and b are integers refers to a straight or branched chain alkenyl moiety having from a to b carbon atoms having at least one double bond of either E or Z stereochemistry where applicable.
• the term includes, for example, vinyl, allyl, 1- and 2-butenyl and 2-methyl-2-propenyl.
• divalent (C a -C b )alkenylene radical means a hydrocarbon chain having from a to b carbon atoms, at least one double bond, and two unsatisfied valences.
• C a -C b alkynyl wherein a and b are integers refers to straight chain or branched chain hydrocarbon groups having from a to b carbon atoms and having in addition at least one triple bond. This term would include for example, ethynyl, 1-propynyl, 1- and 2-butynyl, 2-methyl-2-propynyl, 2-pentynyl, 3- pentynyl, 4-pentynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl and 5-hexynyl.
• divalent (C a -C b )alkynylene radical wherein a and b are integers refers to a divalent hydrocarbon chain having from a to b carbon atoms, and at least one triple bond.
• Carbocyclic refers to a mono-, bi- or tricyclic radical having up to 16 ring atoms, all of which are carbon, and includes aryl and cycloalkyl.
• cycloalkyl refers to a monocyclic saturated carbocyclic radical having from 3-8 carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl. cyclooctyl and bicyclo[2.2.1]hept-1-yl.
• aryl refers to a mono-, bi- or tri-cyclic carbocyclic aromatic radical, and includes radicals having two monocyclic carbocyclic aromatic rings which are directly linked by a covalent bond.
• Illustrative of such radicals are phenyl, biphenyl and naphthyl.
• heteroaryl refers to a mono-, bi- or tri-cyclic aromatic radical containing one or more heteroatoms selected from S, N and O, and includes radicals having two such monocyclic rings, or one such monocyclic ring and one monocyclic aryl ring, which are directly linked by a covalent bond.
• Illustrative of such radicals are thienyl, benzothienyl, furyl, benzfuryl, pyrrolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, pyrazolyl, oxazolyl, benzoxazolyl, isoxazolyl, benzisoxazolyl, isothiazolyl, triazolyl, benztriazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl and indazolyl.
• heterocyclyl or “heterocyclic” includes “heteroaryl” as defined above, and in its non-aromatic meaning relates to a mono-, bi- or tri-cyclic non-aromatic radical containing one or more heteroatoms selected from S, N and O, and to groups consisting of a monocyclic non-aromatic radical containing one or more such heteroatoms which is covalently linked to another such radical or to a monocyclic carbocyclic radical.
• radicals are azetidinyl, pyrrolyl, furanyl, thienyl, piperidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, pyrazolyl, pyridinyl, pyrrolidinyl, pyrimidinyl, morpholinyl, piperazinyl, indolyl, morpholinyl, benzfuranyl, pyranyl, isoxazolyl, benzimidazolyl, methylenedioxyphenyl, ethylenedioxyphenyl, maleimido and succinimido groups.
• substituted as applied to any moiety herein means substituted with up to four compatible substituents, each of which independently may be, for example, (Ci-C ⁇ jalkyl, (C 2 - C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 1 -QOaIkOXy, hydroxy, hydroxy(C r C 6 )alkyl, (C 1 - C 3 )alkoxy(C r C 3 )alkyl, mercapto, mercapto(C r C 6 )alkyl, (C r C 6 )alkylthio, halo (including fluoro, bromo and chloro), fully or partially fluorinated (Ci-C 3 )alkyl, (C 1 - C 3 )alkoxy or (C r C 3 )alkylthio such as trifluoromethyl, trifluorometh
• salt includes base addition, acid addition and quaternary salts.
• Compounds of the invention which are acidic can form salts, including pharmaceutically acceptable salts, with bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-methyl-D-glucamine, choline tris(hydroxymethyl)amino-methane, L-arginine, L-lysine, N-ethyl piperidine, dibenzylamine and the like.
• bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-methyl-D-glucamine, choline tris(hydroxymethyl)amino-methane, L-arginine, L-lysine, N-ethyl pipe
• hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid and the like
• organic acids e.g. with acetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic, p-toluenesulphonic, benzoic, benzenesunfonic, glutamic, lactic, and mandelic acids and the like.
• suitable salts see Handbook of Pharmaceutical Salts: Properties. Selection, and Use by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).
• 'solvate' is used herein to describe a molecular complex comprising the compound of the invention and a stoichiometric amount of one or more pharmaceutically acceptable solvent molecules, for example, ethanol.
• solvent molecules for example, ethanol.
• 'hydrate' is employed when said solvent is water.
• Z is N or CH, or CF. Presently it is preferred that Z be CH, so that the compounds (I) are substituted benzothiazoles.
• X may be, for example, -C(O)O- or -C(O)NH-.
• m may be O and Q may be, for example, hydrogen, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
• m may be 1 and Q hydrogen, with AIk being, for example - CH 2 -, -(CH 2 ) 2 - or -(CH 2 ) 3 -.
• AIk is, when m is 1 it is preferred that X be -C(O)NH-, AIk be -(CH 2 J 2 - and Q be hydrogen.
• R 3 is a group Q 4 -[Alk 2 ] p -[Q 3 ] q - other than hydrogen.
• q is 1 and p is O or 1.
• q is O and p is O or 1.
• Q 3 when present is an optionally substituted divalent monocyclic carbocyclic radical, or an optionally substituted heterocyclic radical having 5 or 6 ring atoms, or an optionally substituted divalent bicyclic carbocyclic or heterocyclic radical having 9 or 10 ring atoms.
• radicals include those having optionally substituted thienyl, benzothienyl, furyl, benzfuryl, pyrrolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, pyrazolyl, oxazolyl, benzoxazolyl, isoxazolyl, benzisoxazolyl, isothiazolyl, triazolyl, benztriazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl, indazolyl.
• azetidinyl pyrrolyl, furanyl, thienyl, piperidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, pyrazolyl, pyridinyl, pyrrolidinyl, pyrimidinyl, piperidinyl, piperazinyl, indolyl, morpholinyl, benzfuranyl, pyranyl, isoxazolyl, benzimidazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, and naphthyl rings.
• Q 4 is hydrogen, an optional substituent, or optionally substituted carbocyclic or heterocyclic ring having 3-7 ring atoms.
• Optional substituents include those particularised above in the discussion of the term "optional substituent”.
• Carbocyclic or heterocyclic rings having 3-7 ring atoms include those monocyclic rings listed in the preceding paragraph, as well as cyclopentyl and homopiperazinyl rings.
• Q 3 be present (ie q is 1 ), and in such cases Q 3 may be, for example, an optionally substituted pyridine ring, an optionally substituted pyrimidine ring or an optionally substituted pyrazine ring, such as an optionally substituted pyridine-2-yl ring, an optionally substituted pyrimidine-2-yl ring or an optionally substituted pyrazine-2-yl ring.
• Optional substituents in Q 3 include CH 3 O-, -NH 2 , -CN, Cl, CH 3 -, and -CF 3 .
• Q 4 may be one of the optional substituents particularised above, for example, halo such as chloro or bromo, -CONHR A , -NHCONHR 6 wherein R A and R B are hydrogen or a (C r C 6 )alkyl, hydroxyCCi-C ⁇ Jalkyl, or (CrC 3 )alkoxy(C 1 -C 3 )alkyl group.
• halo such as chloro or bromo
• -CONHR A -NHCONHR 6
• R A and R B are hydrogen or a (C r C 6 )alkyl, hydroxyCCi-C ⁇ Jalkyl, or (CrC 3 )alkoxy(C 1 -C 3 )alkyl group.
• R 3 groups include the following:
• R 2 is a group Q 1 -[Alk 1 ] q -Q 2 -.
• AIk 1 when present is an optionally substituted, divalent, straight chain or branched CrC 6 alkylene, or C 2 -C 6 alkenylene or C 2 -C 6 alkynylene radical which may contain or terminate in an ether (-O-), thioether (-S-) or amino (-NR)- link.
• Q 2 is an optionally substituted divalent monocyclic carbocyclic or heterocyclic radical having 5 or 6 ring atoms or an optionally substituted divalent bicyclic carbocyclic or heterocyclic radical having 9 or 10 ring atoms.
• examples of such radicals include those specified above in the discussion of radical Q 3 .
• Q 1 is hydrogen, an optional substituent, or an optionally substituted carbocyclic or heterocyclic radical having 3-7 ring atoms.
• examples of such radicals include those specified above in the discussion of radical Q 4 .
• Q 2 may be an optionally substituted divalent nitrogen-containing heterocyclic radical having 5 or 6 ring atoms, such as an optionally substituted divalent pyridonyl, pyridyl, pyrazolyl, pyrimidinyl, thiazolyl, or pyrrolyl radical, or Q 2 when present may be a divalent nitrogen-containing bicyclic carbocyclic or heterocyclic radical having 9 or 10 ring atoms, such as quinolinyl, isoquinolinyl, benzimidazolyl or 5-azaindolyl.
• Q 2 rings include optionally substituted pyridine, pyrimidine, pyrazine or pyridine-2-one rings, such as an optionally substituted pyridine-3-yl ring, an optionally substituted pyrimidine-5-yl ring, an optionally substituted pyrazine-2-yl ring or an optionally substituted pyridine-2- one-4-yl ring.
• Presently preferred optional substituents in Q 2 include CH 3 -, CH 3 O-, - CN, and -NH 2 .
• AIk 1 is present and may be, for example, an optionally substituted divalent C 1 -C 3 alkylene radical which may optionally include an -NH- link, or optionally terminate in an -NH- link to Q 2 .
• Q 1 may be, for example, hydrogen, or an optional substituent as particularised above.
• Q 1 is a group of formula -NR A R B , wherein R A and R B are independently hydrogen or a (C r C 6 )alkyl, hydroxy(C r C 6 )alkyl, or (C r C 3 )alkoxy(Ci-C 3 )alkyl group, or R A and R B taken together with that nitrogen form a cyclic amino ring, for example, a piperidine, morpholine, thiomorpholine, azetidine, pyrrolidine or piperazine ring, the latter being optionally N- substituted by C 1 -C 3 alkyl.
• R 2 groups include the following:
• the compounds with which the invention are concerned are antimicrobially active, and may therefore be of use as topical antibacterial disinfectants, or in the treatment of microbial infection in humans and non-human animals e.g. other mammals, birds and fish.
• the type Il topoisomerase target of the compounds of the invention is a universal bacterial enzyme
• the compounds of the invention inhibit growth of a variety of bacterial species, of the Gram-positive and/or Gram negative classes and atypical bacteria, such as staphylococci, enterococci, streptococci, haemophili, moraxellas, chlamydophilas, legionellas and mycoplasmas for example Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Enterococcus faecium, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Moraxella catarrhalis, Chla
• the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy. Optimum dose levels and frequency of dosing will be determined by clinical trial as is required in the art.
• the compounds with which the invention is concerned may be prepared for administration by any route consistent with their pharmacokinetic properties.
• the orally administrable compositions may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical, or sterile parenteral solutions or suspensions.
• Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinyl-pyrrolidone; fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricant, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants for example potato starch, or acceptable wetting agents such as sodium lauryl sulphate.
• the tablets may be coated according to methods well known in normal pharmaceutical practice.
• Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
• Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; nonaqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
• suspending agents for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats
• emulsifying agents for example lecithin, sorbitan monooleate, or acacia
• nonaqueous vehicles which may include edible oils
• almond oil fractionated coconut oil
• oily esters such as glycerine, propylene glycol
• the drug may be made up into a cream, lotion or ointment.
• Cream or ointment formulations which may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceutics such as the British Pharmacopoeia.
• the drug may be made up into a solution or suspension in a suitable sterile aqueous or non aqueous vehicle.
• Additives for instance buffers such as sodium metabisulphite or disodium edeate; preservatives including bactericidal and fungicidal agents such as phenyl mercuric acetate or nitrate, benzalkonium chloride or chlorhexidine, and thickening agents such as hypromellose may also be included.
• the active ingredient may also be administered parenterally in a sterile medium.
• the drug can either be suspended or dissolved in the vehicle.
• adjuvants such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.
• Step 6 7-Bromo-5-iodo-benzothiazol-2-ylamine and 5-Bromo-7-iodo- benzothiazol-2-ylamine.
• Step 7 1-(7-Bromo-5-iodo-benzothiazol-2-yl)-3-ethyl-urea and 1-(5-Bromo-7- iodo-benzothiazol-2-yl)-3-ethyl-urea.
• Step 8 1-(5-Bromo-7-pyridin-3-yl-benzothiazol-2-yl)-3-ethyl-urea [Example 2] and 1-(7-Bromo-5-pyridin-3-yl-benzothiazol-2-yl)-3-ethyl-urea. [Example 3]
• Step 7. 1-(5-Bromo-7-pyridin-3-yl-benzothiazol-2-yl)-3-ethyl-urea.
• Example 2 1-(7-Bromo-5-pyridin-3-yl-benzothiazol-2-yl)-3-ethyl-urea.
• Example 3 1-(5,7-Di-pyridin-3-yl-benzothiazol-2-yl)-3-ethyl-urea.
• Example 4 [Example 4]
• reaction mixture was then again degassed for 30 min and heated at 12O 0 C for 1h under nitrogen atmosphere.
• DMF was distilled off, water was added into reaction mixture and extracted with ethyl acetate (x 3).
• the combined organic layer was dried over anhydrous Na 2 SO 4 , and evaporated to dryness under reduced pressure.
• the compound was purified over silica (230-400 M) using ethyl acetate/hexane (gradient) to provide the desired compounds.
• Step 7 1-Ethyl-3-(5-iodo-7-pyridin-3-yl-benzothiazol-2-yl)-urea [Example 8] and 1-Ethyl-3-(7-iodo-5-pyridin-3-yl-benzothiazol-2-yl)-urea [Example 9].
• reaction mixture was then again degassed for half an hour and heated at 12O 0 C for 2 h under nitrogen atmosphere.
• DMF was distilled off; water was added to the reaction mixture and extracted with ethyl acetate. The combined organic layers were dried over anhydrous Na 2 SO 4 , and evaporated to dryness under reduced pressure.
• the crude residue was purified over silica gel (230-400 M) using EtOAc-Hexane (70:30) to provide the title compound (0.066 g, 22%).
• Step 1 1 -[5-(5,5-Dimethyl-[1 ,3,2]dioxaborinan-2-yl)-7-pyridin-3-yl-benzothiazol- 2-yl]-3-ethyl-urea.
• reaction mixture from step 1 was cooled to ambient temperature.
• 2- Chloropyrazine 46mg, 0.405mmol
• aqueous cesium carbonate solution 3.M 1 0.1ml, 0.405mmol.
• the reaction mixture was purged with nitrogen for 5 minutes, treated with tetrakistriphenylphosphine palladium (0) (21 mg, 0.0265mmol), sealed and heated at 80°C for 8h.
• reaction mixture was cooled to ambient temperature, diluted with dichloromethane (50ml), washed with water (3X1 OmI) followed by brine (25ml) and dried (MgSO 4 ).
• the solvent was removed in vacuo and the residue purified by flash silica chromatography eluting with 5% methanol in ethyl acetate to give1-Ethyl-3-(5-pyrazin-2-yl-7-pyridin-3-yl-benzothiazol- 2-yl)-urea as a pale brown solid (15mg, 15% over 2 steps).
• Step 1 1-[7-(5,5-Dimethyl-[1,3,2]dioxaborinan-2-yl)-5-pyridin-3-yl-benzothiazol- 2-yl]-3-ethyl-urea
• the reaction mixture from step 1 was cooled to ambient temperature and treated with 2-chloro-3-fluoro-pyridine (15mg, O.Hmmol) and cesium carbonate (53mg, 0.165mmol).
• the reaction mixture was purged with nitrogen for 5 minutes, treated with tetrakis triphenylphosphine palladium (O) (13mg, 0.011mmol), sealed and heated at 80 0 C for 8h.
• the reaction mixture was cooled to ambient temperature, diluted with dichloromethane (50ml), washed with water (3XIOmL) followed by brine (25 ml) and dried (MgSO 4 ).
• Step 1 1-[7-(5,5-Dimethyl-[1,3,2]dioxaborinan-2-yl)-5-pyridin-3-yl-benzothiazol- 2-yl]-3-ethyl-urea.
• Step 1 1-[5-(5,5-Dimethyl-[1,3,2]dioxaborinan-2-yl)-7-pyridin-3-yl-benzothiazol- 2-yl]-3-ethyl-urea
• the resultant mixture was stirred in the cold for 15 min and then added to a suspension of copper (I) thiocyanate (1.0 g) in water (4 ml) whilst cooling in an ice-bath.
• the mixture was stirred in the cold for 2 h and then heated to 7O 0 C for 20 min. After cooling to ambient temperature, the mixture was poured into a saturated aqueous solution of sodium hydrogen carbonate (200 ml) and extracted with ethyl acetate (3x 100 ml) which was washed with brine (200 ml) and dried (MgSO 4 ).
• Step 5 1-Ethyl-3-(7-nitro-5-pyridin-3-yl-benzothiazol-2-yl)-urea.
• Step 1 5-Bromo-3-nitro-2-(2,2,2-trifluoro-acetylamino)-benzoic acid methyl ester.
• the resultant mixture was concentrated by evaporation, the residue diluted with saturated aqueous sodium hydrogen carbonate solution (300 ml) and extracted with ethyl acetate (3x250 ml) which was washed with brine (300 ml) and dried (MgSO 4 ). The solvent was removed in vacuo to give the crude product which was purified by flash chromatography (silica) eluting with 10% to 90% ethyl acetate in 40-60 petroleum ether.
• Step 4 S-Nitro- ⁇ -pyridin-S-yl ⁇ -thiocyanato-benzoic acid methyl ester.
• the resultant mixture was stirred in the cold for 15 min and then added to a suspension of copper (I) thiocyanate (0.71 g) in water (2.8 ml) whilst cooling in an ice-bath.
• the mixture was stirred in the cold for 2 h and then heated to 7O 0 C for 20 min. After cooling to ambient temperature, the mixture was poured into a saturated aqueous solution of sodium hydrogen carbonate (200 ml) and extracted with ethyl acetate (3x 100 ml) which was washed with brine (200 ml) and dried (MgSO 4 ).
• reaction mixture was then again degassed and heated at 12O 0 C for 8h under nitrogen atmosphere. After the completion of the reaction (TLC monitoring), DMF was distilled off; water was added to the reaction mixture and extracted with ethyl acetate. The combined organic layers were dried over anhydrous Na 2 SO 4 , and evaporated to dryness under reduced pressure. The crude residue was purified over silica gel (230-400 M) using EtOAc-Hexane (80:20) to provide the title compound as off white solid (0.012 g, 6%).
• reaction mixture was stirred at -78 0 C for 30 min and then allowed to stir at 0-5 0 C for 2h. The reaction mixture was then allowed to come to room temperature. After the completion of reaction (TLC monitoring), the reaction mass was cooled to O 0 C and water was added slowly. The aqueous phase was extracted with diethyl ether (3x 20 mL). The combined organic layers were dried over anhydrous Na 2 SO 4 , and evaporated to dryness. The crude residue was purified over silica gel (230-400 M) using EtOAc-Hexane (2:98) to provide the compound as yellow oil (0.050 g, 7.20%). MS: 455 (M+H) + .
• reaction mixture was stirred at -78 0 C for 30 min and then allowed to stir at 0-5 0 C for 1h. The reaction mixture was then allowed to stir at room temperature for 16 h. After the completion of reaction (TLC monitoring), the reaction mass was cooled to O 0 C and water was added slowly. The aqueous phase was extracted with diethyl ether (3x 20 mL). The combined organic layers were dried over anhydrous Na 2 SO 4 , and evaporated to dryness. The crude residue was carried foreard to the next step without further purification. MS: 413.22.
• Toluene was distilled off, added water and extracted with DCM. The combined organic layers were dried over anhydrous Na 2 SO 4 , and evaporated to dryness under reduced pressure. The crude residue was purified over silica gel (100-200 M) using DCM-MeOH (96:4) to provide the title compound as off white solid (2.5 mg, 6%).
• Step-1 1-Ethyl-3-[7-(5-methyl-pyridin-2-yl)-5-pyridin-3-yl-benzothiazol-2-yl]-urea [Example 175]
• Step 4 3-Benzyloxy-5-bromo-phenylamine To a solution of 3-benzyloxy-5-bromo-nitrobenzene (27.0 g, 87.60 mmol) in THF (800.0 mL) was added SnCI 2 .2H 2 O (99.0 g, 438.30 mmol) and the resulting reaction mixture was heated to reflux at 65 0 C for 2 h. The reaction mass was then cooled to 0-5 0 C and basified with a saturated solution of NaHCO 3 till pH 8 and then extracted with EtOAc (3 x 1.0 L). The combined organics was dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure.
• 2-chloro-4-cyanopyridine (208mg, 1.5mmol) was added followed by aqueous cesium carbonate solution (3.7M, 0.405ml, 1.5mmol).
• the reaction mixture was purged with nitrogen for 5 minutes, treated with tetrakistriphenylphosphine palladium (0) (115mg, O.i mmol), sealed and heated at 80 0 C for 8h.
• the reaction mixture was cooled to ambient temperature, diluted with ethylacetate (150ml), washed with water (3X20ml) followed by brine (25ml) and dried (MgSO 4 ).
• Step 10 1-[7-(5-Cyano-pyridin-2-yl)-5-hydroxy-benzothiazol-2-yl]-3-ethyl-urea.
• Solvents - Acetonitrile (Far UV grade) with 0.1% (V/V) formic acid
• MS detection Either Micromass Platform or ZQ, Both single quadrapole LC-MS instruments.
• Typical ESI voltages and temperatures are: Source 120-15OC 3.5KV capillary 25V cone
• Typical APCI voltages and temperatures are:
• MICs for compounds against each strain were determined by the broth microdilution or agar dilution method according to the guidelines of the Clinical Laboratories and Standards Institute, formerly the National Committee for Clinical Laboratory Standards (Clinical Laboratories and Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Seventh Edition. Document M7-A7. CLSI 1 Wayne, Pa, 2006; Clinical Laboratories and Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard-Sixth Edition. Document M11-A6. CLSI, Wayne, Pa, 2004). MICs against Chlamydia trachomatis and Chlamydophila pneumoniae were measured using the microtitre tissue culture incorporation technique with demonstration of inclusions by immunofluorescence straining.
• Gyrase converts ATP into ADP and inorganic phosphate.
• the released phosphate can be detected by the addition of malachite green solution and measured by monitoring the increase in absorbance at 600nm.
• the ATPase assay is carried out in a buffer containing 4.8 ⁇ g/ml Gyrase enzyme (A 2 B 2 complex from Escherichia coli), 0.08 ⁇ g/ml ssDNA, 35 mM Tris pH 7.5, 24 mM KCI, 2 mM MgCI 2 , 6.5% Glycerol, 2 mM DTT, 1.8 mM Spermidine, 0.5 mg/ml BSA, and 5% DMSO solution containing the inhibitor.
• the reaction is started by adding ATP to a final concentration of 1 mM and allowed to incubate at 3O 0 C for 60 minutes.
• the reaction is stopped by adding 200 ⁇ l of malachite green solution (0.034% malachite green, 10 mM ammonium molybdate, 1 M HCI, 3.4% ethanol, 0.01% tween 20). Colour is allowed to develop for 5 minutes and the absorbance at 600 nm is measured spectrophotometrically. The IC 50 values are determined from the absorbance readings using no compound and no enzyme controls.
• Example compounds above of the current invention were found to inhibit the gyrase ATPase assay described above, with 50% inhibitory concentrations (IC 50 ) of less than 0.75 micro molar.
• Table 2 shows the MIC value for each Example against Enterococcus faecalis ATCC 29212 in the MIC Assay described above.
• Examples with activity “C” demonstrate MICs of 2-16 ⁇ g/ml.
• Examples with activity “B” demonstrate MICs of 0.25-1 ⁇ g/ml.
• Examples with activity “A” demonstrate MICs of ⁇ 0.25 ⁇ g/ml.
• Some of the Example compounds were also tested for activity against other bacterial species.
• Table 3 shows the MICs of Example 163 against various bacterial species.
• Activity "C” demonstrates an MIC of 2-16 ⁇ g/ml.
• Activity “B” demonstrates an MIC of 0.25-1 ⁇ g/ml.
• Activity "A” demonstrates an MIC of ⁇ 0.25 ⁇ g/ml.
• Example compounds were also tested for activity in a mouse Staphylococcus aureus septicaemia model of infection.
• Table 4 shows the survival at day 7 of infected mice treated as indicated with one or two intraperitoneal doses of each of the compounds of Examples 4, 91 and 163 at 1 hour or 1 and 6 hours after intraperitoneal inoculation with a lethal dose of Staphylococcus aureus.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Thiazole And Isothizaole Compounds (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Priority Applications (18)

Applications Claiming Priority (2)

Related Parent Applications (3)

Related Child Applications (3)

Publications (1)

Family

ID=36803739

Family Applications (1)

Country Status (21)

Cited By (47)

Families Citing this family (4)

Citations (8)

Family Cites Families (2)

• 2006
  • 2006-06-22 GB GBGB0612428.3A patent/GB0612428D0/en not_active Ceased
• 2007
  • 2007-06-21 PL PL07733310T patent/PL2034997T3/pl unknown
  • 2007-06-21 SG SG2011040847A patent/SG172676A1/en unknown
  • 2007-06-21 EP EP20070733310 patent/EP2034997B1/en not_active Not-in-force
  • 2007-06-21 ES ES07733310T patent/ES2403005T3/es active Active
  • 2007-06-21 CN CN200780023251XA patent/CN101472585B/zh not_active Expired - Fee Related
  • 2007-06-21 US US12/304,303 patent/US7977340B2/en not_active Expired - Fee Related
  • 2007-06-21 PT PT07733310T patent/PT2034997E/pt unknown
  • 2007-06-21 MY MYPI20085070 patent/MY148682A/en unknown
  • 2007-06-21 EA EA200900047A patent/EA019748B1/ru not_active IP Right Cessation
  • 2007-06-21 BR BRPI0713501-7A patent/BRPI0713501A2/pt not_active IP Right Cessation
  • 2007-06-21 MX MX2008015706A patent/MX2008015706A/es active IP Right Grant
  • 2007-06-21 JP JP2009515958A patent/JP5309021B2/ja not_active Expired - Fee Related
  • 2007-06-21 DK DK07733310T patent/DK2034997T3/da active
  • 2007-06-21 KR KR1020097001499A patent/KR101443795B1/ko not_active Expired - Fee Related
  • 2007-06-21 CA CA2655403A patent/CA2655403C/en not_active Expired - Fee Related
  • 2007-06-21 WO PCT/GB2007/002314 patent/WO2007148093A1/en not_active Ceased
  • 2007-06-21 NZ NZ574313A patent/NZ574313A/en not_active IP Right Cessation
  • 2007-06-21 AU AU2007262791A patent/AU2007262791B2/en not_active Ceased
• 2008
  • 2008-12-03 IL IL195687A patent/IL195687A/en active IP Right Grant
• 2009
  • 2009-01-12 ZA ZA2009/00240A patent/ZA200900240B/en unknown
• 2011
  • 2011-06-07 US US13/154,592 patent/US8389516B2/en not_active Expired - Fee Related

Patent Citations (8)

Also Published As

Similar Documents

Legal Events